Compare VanEck Junior Gold Miners (GDXJ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs ResMed Inc. — how do they compare? VanEck Junior Gold Miners trades at $92.57, while ResMed Inc. trades at $202.52 (market cap $28.80B). The key difference: ResMed Inc. pays a 1.21% dividend while VanEck Junior Gold Miners pays none, and VanEck Junior Gold Miners is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| GDXJ | RMD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $293.73 |
52-Week Low | $64.22 | $182.82 |
Market Cap | — | $28.80B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ is trading at $92.16, down 6.31% over the past 24 hours amid bearish technical signals. The ETF shows weakness with moving averages indicating strong selling pressure while oscillators remain neutral. Recent news highlights GDXJ's underperformance compared to peers and questions about its small-cap exposure composition.
The outlook remains cautious with technical indicators favoring sellers and fundamental concerns about portfolio composition. Investment opportunities exist for contrarian investors betting on gold miner recovery, but risks include continued underperformance and market volatility. The bearish technical setup suggests near-term pressure may persist.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
